Partnership For Allogeneic Cell-based Cancer Immunotherapies
Filed with ASX · · 2 pages · English
In the deck
Earlier from Mesoblast
- MSB Enters Into $75 Million Non-Dilutive Credit Facility
- GVHD Day 28 Results Presentation
- Primary Endpoint Successfully Achieved in MSB P3 GVHD Trial
- Appendix 3B with prospectus
- Mesoblast Receives RMAT For LVAD Heart Failure Patients
Later from Mesoblast
- Key Day 100 Survival Results In P3 GvHD Trial
- MSB Enters Into US$50M Financing With NovaQuest Capital
- MSB Enters Into Cardiovascular Alliance For China With Tasly
- Update on Tasly transaction
- Mesoblast Reports on Annual and Fourth Quarter Results
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast